Idiopathic Pulmonary Fibrosis: all 565 studies

Page 3 of 6. Open to participants first (117), then studies with results posted, then the rest; newest registration first within each.

• RCT (Randomized Control Trial) of TD139 vs Placebo in HV's (Human Volunteers) and IPF PatientsCompletedNCT02257177Phase 1/2Results posted
• Bardoxolone Methyl Evaluation in Patients With Pulmonary Hypertension (PH) - LARIATCompletedNCT02036970Phase 2Results posted
• D2212C00002 J-Phase II StudyCompletedNCT02036580Phase 2Results posted
• The NIH Exercise Therapy for Advanced Lung Disease Trials: Response and Adaptation to Aerobic Exercise in Patients With Interstitial Lung DiseaseCompletedNCT02019641Not applicableResults posted
• Treatment of IPF With Laparoscopic Anti-Reflux SurgeryCompletedNCT01982968Not applicableResults posted
• Nintedanib Twice Daily vs Placebo in Patients Diagnosed With Idiopathic Pulmonary Fibrosis (IPF)CompletedNCT01979952Phase 3Results posted
• Autoantibody Reduction Therapy in Patients With Idiopathic Pulmonary FibrosisCompletedNCT01969409Phase 2Results posted
• Evaluate the Safety and Efficacy of FG-3019 (Pamrevlumab) in Participants With Idiopathic Pulmonary Fibrosis (IPF)CompletedNCT01890265Phase 2Results posted
• A Study of Lebrikizumab in Participants With Idiopathic Pulmonary Fibrosis (IPF)CompletedNCT01872689Phase 2Results posted
• Study to Assess the Efficacy and Safety of Simtuzumab (GS-6624) in Adults With Idiopathic Pulmonary Fibrosis (IPF)TerminatedNCT01769196Phase 2Results posted
• Safety and Efficacy of a Lysophosphatidic Acid Receptor Antagonist in Idiopathic Pulmonary FibrosisCompletedNCT01766817Phase 2Results posted
• Long-Term Safety Study of GS-6624 in Adults With Idiopathic Pulmonary Fibrosis (IPF)TerminatedNCT01759511Phase 2Results posted
• A Phase 2, Randomized Dose-ranging Study to Evaluate the Efficacy of Tralokinumab in Adults With Idiopathic Pulmonary FibrosisTerminatedNCT01629667Phase 2Results posted
• Extension Trial of the Long Term Safety of BIBF 1120 in Patients With Idiopathic Pulmonary FibrosisCompletedNCT01619085Phase 3Results posted
• Clinical Trial of Low Dose Oral Interferon Alpha in Idiopathic Pulmonary FibrosisCompletedNCT01442779Phase 2Results posted
• A Study to Evaluate the Potential Role of Mesenchymal Stem Cells in the Treatment of Idiopathic Pulmonary FibrosisCompletedNCT01385644Phase 1Results posted
• STX-100 in Patients With Idiopathic Pulmonary Fibrosis (IPF)CompletedNCT01371305Phase 2Results posted
• Efficacy and Safety of Pirfenidone in Patients With Idiopathic Pulmonary Fibrosis (IPF)CompletedNCT01366209Phase 3Results posted
• Safety and Efficacy of BIBF 1120 at High Dose in Idiopathic Pulmonary Fibrosis Patients IICompletedNCT01335477Phase 3Results posted
• Safety and Efficacy of BIBF 1120 at High Dose in Idiopathic Pulmonary Fibrosis PatientsCompletedNCT01335464Phase 3Results posted
• Combined PEX, Rituximab and Steroids in Acute Idiopathic Pulmonary Fibrosis ExacerbationsCompletedNCT01266317Phase 1/2Results posted
• A Phase 1b Study of IV PRM151 in Patients With Idiopathic Pulmonary Fibrosis (IPF)CompletedNCT01254409Phase 1Results posted
• Study of Inhaled Carbon Monoxide to Treat Idiopathic Pulmonary FibrosisCompletedNCT01214187Phase 2Results posted
• Roll Over Study From 1199.30 BIBF 1120 in Idiopathic Pulmonary Fibrosis (IPF)CompletedNCT01170065Phase 2Results posted
• Safety and PK Study of BIBF 1120 in Japanese Patients With IPFCompletedNCT01136174Phase 2Results posted
• Rehabilitation of Idiopathic Pulmonary Fibrosis (IPF) PatientsCompletedNCT01118221Not applicableResults posted
• Targeting Vascular Reactivity in Idiopathic Pulmonary FibrosisTerminatedNCT00981747Phase 2/3Results posted
• AntiCoagulant Effectiveness in Idiopathic Pulmonary FibrosisTerminatedNCT00957242Phase 3Results posted
• Macitentan Use in an Idiopathic Pulmonary Fibrosis Clinical StudyCompletedNCT00903331Phase 2Results posted
• Losartan in Treating Patients With Idiopathic Pulmonary FibrosisCompletedNCT00879879Not applicableResults posted
• ARTEMIS-PH - Study of Ambrisentan in Subjects With Pulmonary Hypertension Associated With Idiopathic Pulmonary FibrosisTerminatedNCT00879229Phase 3Results posted
• (ARTEMIS-IPF) Randomized, Placebo-Controlled Study to Evaluate Safety and Effectiveness of Ambrisentan in IPFTerminatedNCT00768300Phase 3Results posted
• Treprostinil Therapy For Patients With Interstitial Lung Disease And Severe Pulmonary Arterial HypertensionCompletedNCT00705133Phase 2Results posted
• Effects of Inhaled Treprostinil Sodium for the Treatment of Pulmonary Hypertension Associated With Idiopathic Pulmonary FibrosisTerminatedNCT00703339Phase 2Results posted
• Open-Label Study of the Long Term Safety of Pirfenidone in Patients With Idiopathic Pulmonary Fibrosis (IPF)CompletedNCT00662038Phase 3Results posted
• Open Label Extension Study in Patients With Idiopathic Pulmonary Fibrosis Who Completed Protocol AC-052-321/ BUILD 3 / NCT00391443CompletedNCT00631475Phase 3Results posted
• Treatment of Chronic Cough in Idiopathic Pulmonary Fibrosis With ThalidomideCompletedNCT00600028Phase 3Results posted
• Sildenafil Trial of Exercise Performance in Idiopathic Pulmonary FibrosisCompletedNCT00517933Phase 3Results posted
• Safety And Efficacy of BIBF 1120 in Idiopathic Pulmonary FibrosisCompletedNCT00514683Phase 2Results posted
• BUILD 3: Bosentan Use in Interstitial Lung DiseaseCompletedNCT00391443Phase 3Results posted
• Safety and Efficacy of Pirfenidone in Patients With Idiopathic Pulmonary FibrosisCompletedNCT00287729Phase 3Results posted
• Three-Arm Study of the Safety and Efficacy of Pirfenidone in Patients With Idiopathic Pulmonary FibrosisCompletedNCT00287716Phase 3Results posted
• EZ-2053 in the Prophylaxis of Acute Pulmonary Allograft RejectionCompletedNCT00105183Phase 3Results posted
• Safety Study of Oral Pirfenidone in Patients With Pulmonary Fibrosis/Idiopathic Pulmonary FibrosisCompletedNCT00080223Phase 2Results posted
• Emotional and Social Experiences of Antifibrotic (AF) Therapy Among Idiopathic Pulmonary Fibrosis (IPF)/Progressive Pulmonary Fibrosis (PPF) Patients: A Real-World StudyCompletedNCT07743996
• Validation of AI-Based Detection of Idiopathic Pulmonary Fibrosis in Serial Chest Radiographs: A Retrospective Longitudinal StudyCompletedNCT07712952
• Artificial Intelligence (AI) Detection of Incidental Interstitial Opacity on Chest RadiographyCompletedNCT07686562
• Study To Investigate The Potential DDI Between HEC585 And Pirfenidone/Nintedanib In Healthy SubjectsCompletedNCT07588646Phase 1
• Hereditary Influences on Pulmonary Fibrosis TrajectoriesActive, not recruitingNCT07580053
• Occupational and Environmental Exposures Analysis in Interstitial Lung Diseases.Active, not recruitingNCT07577115
• IPF Longitudinal Natural History StudyActive, not recruitingNCT07560189
• Optimizing the Follow-Up Journey in Interstitial Lung Disease: The OPTIMIZE-ILD-2 TrialActive, not recruitingNCT07486206Not applicable
• A Study to Evaluate Safety, Tolerability and Pharmacokinetics of MNKD-201 in Patients With Idiopathic Pulmonary FibrosisCompletedNCT07344558Phase 1
• A Single and Multiple Ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of GNS-3545 in Healthy ParticipantsCompletedNCT07225296Phase 1
• Sarcopenia in Patients With Idiopathic Pulmonary FibrosisCompletedNCT07178197
• Prognostic Score Comparison in IPF and HPCompletedNCT07169253
• The relatıonshıp Between Upper Extremity Exercise Test and Exercise Capacity ın patıents wıth Idiopathic Pulmonary FibrosisCompletedNCT07119099
• Evaluating the Diagnostic Performance of (HRCT) in IPD Fibrosis in Suspected CasesActive, not recruitingNCT07048652
• A Study to Find Out Whether BI 765423 Has an Effect on Lung Function in People With Idiopathic Pulmonary Fibrosis (IPF) With or Without Standard TreatmentActive, not recruitingNCT07036523Phase 2
• NAL ER IPF Respiratory Function and Safety StudyCompletedNCT07036029Phase 1
• WISPer: Evaluation of MTX-463 in Participants With Idiopathic Pulmonary Fibrosis (IPF)Active, not recruitingNCT06967805Phase 2
• Identification of Palliative Care Needs and Prognostic Factors of Survival in Tailoring Appropriate Interventions in Advanced Oncological, Renal and Pulmonary DiseasesCompletedNCT06909968
• A Trial of HRS-9813 in Healthy SubjectsCompletedNCT06821464Phase 1
• Evaluating the Efficacy and Safety of of HSK44459 in People With Idiopathic Pulmonary FibrosisCompletedNCT06764862Phase 2
• A Phase 2 Study of CAL101 in Patients With Idiopathic Pulmonary FibrosisActive, not recruitingNCT06736990Phase 2
• PET Study of PIPE-791 in Healthy Volunteers and Volunteers With PrMS and IPFCompletedNCT06683612Phase 1
• Comparison of the Efficacy of Pirfenidone and Nintedanipine in Pulmonary FibrosisCompletedNCT06650774
• Expand Pulmonary Rehabilitation to Other Chronic Respiratory Diseases Than COPDActive, not recruitingNCT06636487Not applicable
• A Study to Evaluate the Safety, Tolerability and Blood Levels of GSK3915393 Administered to Healthy Participants of Chinese, Japanese and European Ancestry and to Assess Effects of GSK3915393 on NintedanibCompletedNCT06625489Phase 1
• Comparative Pharmacokinetic Study of Pirfenidone Modified-Release Tablets and Pirfenidone Tablets in Healthy Subjects Under Fed ConditionsCompletedNCT06589921Phase 1
• Study to Assess CMR316 in Healthy Volunteers and Patients With Idiopathic Pulmonary FibrosisCompletedNCT06589219Phase 1
• A Trial to Evaluate Efficacy and Safety of Buloxibutid in People With Idiopathic Pulmonary Fibrosis.Active, not recruitingNCT06588686Phase 2
• Comparative Pharmacokinetic(PK) Study of Pirfenidone Modified-Release Tablets and Pirfenidone Tablets in Healthy Subjects Under Fed ConditionsCompletedNCT06588517Phase 1
• Comparative Pharmacokinetic Study of Pirfenidone Modified-Release Tablets in Healthy Subjects Under Fasting and Fed ConditionsCompletedNCT06569381Phase 1
• The Assessment of Nutritional Status of Patients With IPFCompletedNCT06563011Not applicable
• A Single and Multiple Ascending Dose Study to Investigate the Safety, Tolerability, and Pharmacokinetics of AZD8965 in Healthy Participants (Including Japanese and Chinese Participants) and an Open-label Cohort to Assess the Effect of Food on the Pharmacokinetics of AZD8965 in Healthy ParticipantsCompletedNCT06502379Phase 1
• Real-life-persistence to Antifibrotic TreatmentsCompletedNCT06485635
• A Phase 2 Trial of ENV-101 in Patients With Lung Fibrosis (WHISTLE-PF Trial)Active, not recruitingNCT06422884Phase 2
• The Effect Of Baduanjin Exercises In Patients With Idiopathic Pulmonary FibrosisCompletedNCT06372353Not applicable
• A Study to Test Whether BI 1819479 Improves Lung Function in People With Idiopathic Pulmonary Fibrosis (IPF)CompletedNCT06335303Phase 2
• Biomarker Modulation and the Inhibition of NKT1 Cells by Oral GRI-0621 in Patients With IPFCompletedNCT06331624Phase 2
• Collagen-targeted Positron Emission Tomography (PET) Imaging for Assessment of EGCG EffectCompletedNCT06265532Phase 1
• A Study in People With Idiopathic Pulmonary Fibrosis to Test Whether Pirfenidone Influences the Amount of BI 1015550 in the BloodCompletedNCT06241560Phase 2
• A Follow-up Study to Test Long-term Treatment With Nerandomilast in People With Pulmonary Fibrosis Who Took Part in a Previous Study With NerandomilastActive, not recruitingNCT06238622Phase 3
• Safety, Tolerability and Efficacy of VUM02 Injection in Treatment of Idiopathic Pulmonary Fibrosis (IPF)CompletedNCT06230822Phase 1
• The Safety, Tolerability, and Pharmacokinetic Study of SC1011 in Healthy Subjects.CompletedNCT06160440Phase 1
• Safety, Tolerability and Pharmacokinetic Study of SC1011 in Healthy SubjectsCompletedNCT06135363Phase 1
• MAXPIRe: Study to Evaluate Axatilimab in Participants With Idiopathic Pulmonary Fibrosis (IPF)Active, not recruitingNCT06132256Phase 2
• A Clinical Study to Evaluate the Efficacy and Safety of REGEND001 Cell Therapy on Idiopathic Pulmonary Fibrosis (IPF)CompletedNCT06081621Phase 2
• Londrina Activities of Daily Living Protocol in Idiopathic Pulmonary Fibrosis PatientsCompletedNCT06049004
• A Study to Evaluate the Efficacy, Safety, and Tolerability of BMS-986278 in Participants With Idiopathic Pulmonary FibrosisActive, not recruitingNCT06003426Phase 3
• The First-in-human Study of SRN-001 in Healthy ParticipantsCompletedNCT05984992Phase 1
• Efficacy and Safety of ME-015 (Suplatast Tosilate) in Cough Related to Idiopathic Pulmonary Fibrosis (COSMIC-IPF)Active, not recruitingNCT05983471Phase 2
• Safety and Efficacy of Venetoclax in Idiopathic Pulmonary FibrosisCompletedNCT05976217Early Phase 1
• A Study to Investigate Leramistat in Patients With IPFWithdrawnNCT05951296Phase 2
• Anlotinib Capsules in the Treatment for IPF/PF-ILDsActive, not recruitingNCT05828953Phase 2
• A Drug-Drug Interaction Study of ENV-101 (Taladegib) on Nintedanib Pharmacokinetics in Healthy SubjectsCompletedNCT05817240Phase 1
• A Study Evaluating the Efficacy and Safety of Vixarelimab in Participants With Idiopathic Pulmonary Fibrosis and in Participants With Systemic Sclerosis-Associated Interstitial Lung DiseaseTerminatedNCT05785624Phase 2
• An In Silico Trial to Evaluate Prospectively the Performance of a Radiomics Algorithm for UIP Compared to Medical DoctorsCompletedNCT05784207
• Study on Intravenous Injection of SHR-1906 in the Treatment of Idiopathic Pulmonary FibrosisCompletedNCT05722964Phase 2

← Idiopathic Pulmonary Fibrosis overview